Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens

Journal of Cutaneous Pathology

Volumn 38, Issue 7, 2011, Pages 542-550

  Sellheyer, Klaus ^a,b   Nelson, Paula ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Nelson Dermatopathology Associates   (United States)

Author keywords

basal cell carcinoma; cytokeratin 20; PHLDA1; TDAG51; trichoepithelioma

Indexed keywords

CYTOKERATIN 20; PHLDA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BIOPSY; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MERKEL CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, BASAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; MALE; MERKEL CELLS; MIDDLE AGED; SKIN NEOPLASMS; STEM CELLS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79959244922     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2011.01693.x     Document Type: Article

References (40)

1. Fernandez EM, Helm T, Ioffreda M, Helm KF., The vanishing biopsy: the trend toward smaller specimens. Cutis 2005; 76: 335.
2. Sellheyer K, Nelson P, Bergfeld WF., Inadequate biopsy technique and specimen size: an alarming trend that compromises patient care and an appeal to our clinical colleagues. Arch Dermatol 2010; 146: 1180.
3. Smoller BR, Van de Rijn M, Lebrun D, Warnke RA., bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol 1994; 131: 28.
4. Verhaegh ME, Arends JW, Majoie IM, Hoekzema R, Neumann HA., Transforming growth factor-beta and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma. Dermatol Surg 1997; 23: 695.
5. Basarab T, Orchard G, Russell-Jones R., The use of immunostaining for bcl-2 and CD34 and the lectin peanut agglutinin in differentiating between basal cell carcinomas and trichoepitheliomas. Am J Dermatopathol 1998; 20: 448.
6. Swanson PE, Fitzpatrick MM, Ritter JH, Glusac EJ, Wick MR., Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol 1998; 25: 153.
7. Poniecka AW, Alexis JB., An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol 1999; 21: 332.
8. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA, Sangueza OP., Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53. J Cutan Pathol 2000; 27: 169.
9. Lum CA, Binder SW., Proliferative characterization of basal-cell carcinoma and trichoepithelioma in small biopsy specimens. J Cutan Pathol 2004; 31: 550.
10. Vigneswaran N, Haneke E, Peters KP., Peanut agglutinin immunohistochemistry of basal cell carcinoma. J Cutan Pathol 1987; 14: 147.
11. Tsubura A, Fujita Y, Sasaki M, Morii S., Lectin-binding profiles for normal skin appendages and their tumors. J Cutan Pathol 1992; 19: 483.
12. Thewes M, Worret WI, Engst R, Ring J., Stromelysin-3: a potent marker for histopathologic differentiation between desmoplastic trichoepithelioma and morphealike basal cell carcinoma. Am J Dermatopathol 1998; 20: 140.
13. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C., CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol 2006; 33: 123.
14. Kirchmann TT, Prieto VG, Smoller BR., CD34 staining pattern distinguishes basal cell carcinoma from trichoepithelioma. Arch Dermatol 1994; 130: 589.
15. Kirchmann TT, Prieto VG, Smoller BR., Use of CD34 in assessing the relationship between stroma and tumor in desmoplastic keratinocytic neoplasms. J Cutan Pathol 1995; 22: 422.
16. Krahl D, Sellheyer K., Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol 2007; 34: 782.
17. Fernandez-Flores A., Advanced differentiation in trichoepithelioma and basal cell carcinoma investigated by immunohistochemistry against neurofilaments. Folia Histochem Cytobiol 2009; 47: 61.
18. Hartschuh W, Schulz T., Merkel cells are integral constituents of desmoplastic trichoepithelioma: an immunohistochemical and electron microscopic study. J Cutan Pathol 1995; 22: 413.
19. Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE., Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol 2000; 22: 311.
20. Costache M, Bresch M, Böer A., Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology 2008; 52: 865.
21. Izikson L, Bhan A, Zembowicz A., Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol 2005; 27: 91.
22. Vollmer RT., Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma. J Cutan Pathol 2009; 36: 283.
23. Katona TM, Perkins SM, Billings SD., Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol 2008; 35: 174.
24. Krahl D, Sellheyer K., p75 Neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: insights into the histogenesis of adnexal tumours based on embryology and hair follicle biology. Br J Dermatol 2010; 163: 138.
25. Abbas O, Richards JE, Mahalingam M., Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/ infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 2010; 23: 1535.
26. McCalmont TH., A call for logic in the classification of adnexal neoplasms. Am J Dermatopathol 1996; 18: 103.
27. Akiyama M, Smith LT, Shimizu H., Changing patterns of localization of putative stem cells in developing human hair follicles. J Invest Dermatol 2000; 114: 321.
28. Schneider MR, Schmidt-Ullrich R, Paus R., The hair follicle as a dynamic miniorgan. Curr Biol 2009; 19: R132.
29. Ohyama M, Terunuma A, Tock CL, et al., Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 2006; 116: 249.
30. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G., The C8/ 144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 1998; 111: 3179.
31. Pontiggia L, Biedermann T, Meuli M, et al., Markers to evaluate the quality and self-renewing potential of engineered human skin substitutes in vitro and after transplantation. J Invest Dermatol 2009; 129: 480.
32. Park CG, Lee SY, Kandala G, Lee SY, Choi Y., A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Immunity 1996; 4: 583.
33. Sellheyer K, Krahl D., PHLDA1 (TDAG51) is a follicular stem cell marker and differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma. Br J Dermatol. 2011; 164: 141.
34. Kinkelin I, Stucky CL, Koltzenburg M., Postnatal loss of Merkel cells, but not of slowly adapting mechanoreceptors in mice lacking the neurotrophin receptor p75. Eur J Neurosci. 1999; 11: 3963.
35. Neef R, Kuske MA, Pröls E, Johnson JP., Identification of the human PHLDA1/ TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 2002; 62: 5920.
36. Florell SR, Zone JJ, Gerwels JW., Basal cell carcinomas are populated by melanocytes and Langerhans' cells. Am J Dermatopathol 2001; 23: 24.
37. Schubert B, Rudolph P., Basal cell carcinoma: a natural milieu for melanocytes? Am J Dermatopathol 2001; 23: 558.
38. Schreiner TU, Lischka G, Schaumburg-Lever G., Langerhans cells in skin tumors. Arch Dermatol 1995; 131: 187.
39. Nagata T, Takahashi Y, Sugahara M, et al., Profiling of genes associated with transcriptional responses in mouse hippocampus after transient forebrain ischemia using high-density oligonucleotide DNA array. Brain Res Mol Brain Res 2004; 121: 1.
40. Oberg HH, Sipos B, Kalthoff H, Janssen O, Kabelitz D., Regulation of T-cell death-associated gene 51 (TDAG51) expression in human T-cells. Cell Death Differ 2004; 11: 674.